IDiyas

For the Inventor, By the Inventor

Jamaica Plain, MA, United States of America

Dennis Buckley

USPTO Granted Patents = 27 

 

 

Average Co-Inventor Count = 3.6

ph-index = 10

Forward Citations = 334(Granted Patents)


Location History:

  • Jamaica Plains, MA (US) (2018 - 2019)
  • Boston, MA (US) (2017 - 2023)
  • Jamaica Plain, MA (US) (2017 - 2024)
  • Cambridge, MA (US) (2021 - 2024)

Company Filing History:

goldMedal27 out of 1,206 
 
Dana-farber-cancer Institute Inc.
 patents
silverMedal2 out of 1,036 
 
Children's Medical Center Corporation
 patents
where one patent can have more than one assignee

Years Active: 2017-2024

Loading Chart...
Loading Chart...
Loading Chart...
27 patents (USPTO):
1. 12023385 - Tunable endogenous protein degradation with heterobifunctional compounds (2024-07-02),
2. 11944625 - Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies (2024-04-02),
3. 11583586 - Methods to induce targeted protein degradation through bifunctional molecules (2023-02-21),
4. 11578075 - Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use (2023-02-14),
5. 11311609 - Regulating chimeric antigen receptors (2022-04-26),
6. 11306105 - Cyano thienotriazolodiazepines and uses thereof (2022-04-19),
7. 11293023 - Tunable endogenous protein degradation (2022-04-05),
8. 11285218 - Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use (2022-03-29),
9. 11059801 - Methods to induce targeted protein degradation through bifunctional molecules (2021-07-13),
10. 11046954 - Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses (2021-06-29),
11. 10980808 - Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies (2021-04-20),
12. 10925868 - Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use (2021-02-23),
13. 10899768 - Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use (2021-01-26),
14. 10849980 - Methods to induce targeted protein degradation through bifunctional molecules (2020-12-01),
15. 10793571 - Uses of diazepane derivatives (2020-10-06),

Title: The Innovative Path of Inventor Dennis Buckley

Introduction:

Dennis Buckley, a prolific inventor based in Jamaica Plain, MA, has made significant contributions to the field of targeted protein degradation through his groundbreaking patents and research endeavors. With a total of 25 patents under his name, Buckley stands out as a pioneering figure in the development of bifunctional compounds for inducing protein degradation.

Latest Patents:

Buckley's latest patents focus on methods to induce targeted protein degradation through bifunctional molecules. The applications detail the use of compounds that act as protein degradation inducing moieties, with a specific focus on the degradation of endogenous proteins and protein kinases. These innovations hold promise for treating proliferative disorders and disorders modulated by protein kinases, showcasing Buckley's commitment to advancing therapeutic solutions.

Career Highlights:

Throughout his career, Buckley has been associated with esteemed institutions such as the Dana-Farber Cancer Institute Inc. and the Children's Medical Center Corporation. His research and patent applications demonstrate a profound understanding of biochemistry and molecular biology, paving the way for novel approaches to protein degradation and disease treatment.

Collaborations:

Buckley has had the privilege of collaborating with distinguished colleagues in the field, including James Elliott Bradner and Georg Winter. These collaborations have undoubtedly enriched the scope of his work, fostering creativity and innovation in the pursuit of effective therapeutic strategies.

Conclusion:

In conclusion, Dennis Buckley's journey as an inventor exemplifies a relentless pursuit of innovation and scientific excellence. His patents not only reflect his expertise in targeted protein degradation but also underscore his dedication to advancing the field of biomedicine. Buckley's contributions are poised to make a lasting impact on the landscape of medical research and treatment modalities.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…